Today: 20 March 2026
Subscribe
Browse Category

Biotechnology 21 November 2025 - 7 December 2025

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Inovio Pharmaceuticals closed at $2.07 on December 5, up 2.5% for the day and nearly 20% over the past 10 sessions, with volume near 1 million shares. The stock recently crossed its 200-day moving average, while short interest remains high at 34% of daily volume. Wall Street’s average 12-month price target is $9, despite continued losses and minimal revenue.
7 December 2025
···
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna shares closed at $27.70 on December 5, up 8.7% on volume over 16 million. The rally followed a major French study showing no increase in long-term mortality from mRNA COVID vaccines and a new $1.5 billion credit facility. The stock is still down more than 50% over the past year despite recent gains. Year-to-date performance remains negative at –38.7%.
6 December 2025
··
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna shares jumped nearly 9% on December 5, closing at about $27–28 after a large French study backed the long-term safety and effectiveness of mRNA COVID vaccines. The stock remains down roughly 34% year-to-date and trades around 40% below its 52-week high. Investors also weighed a new $1.5 billion loan deal and updated guidance on future growth.
5 December 2025
··
Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (NASDAQ: ADTX) traded around $3 per share midday December 5, 2025, with a market cap near $1.7 million and only 559,000 shares outstanding. The company reported $2,770 in revenue and a $37.6 million net loss for the first nine months of 2025, holding $163,041 in cash as of September 30. ADTX faces ongoing Nasdaq delisting risk after a 1-for-113 reverse split. Trading remains volatile with heavy short interest.
5 December 2025
··
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc Ltd. shares closed at $1.80 on December 5, 2025, after surging on volume above 10 million, following news of a quantum bio-data analytics deal via its NeuroThera subsidiary. The stock remains down over 70% in the past year and trades more than 95% below its 52-week high of $37.59, leaving the company with a market cap near $5.8 million.
5 December 2025
···
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical shares jumped 83% to $3.69 on December 4 after new data on its Emperor Total Artificial Heart was presented at ISMCS 2025 in Vienna. Trading volume soared to nearly 39 million shares. The company’s market cap reached $272 million, but the stock remains down over 70% from its October high of $13.68. After-hours trading showed some profit-taking, with prices around $3.30–$3.40.
5 December 2025
···
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon shares surged over 100% to the mid-teens on December 4, 2025, with volume topping 26 million after announcing a manufacturing milestone for its PL‑14 Allergy Blocker and promising preclinical data for its naloxone hydrogel. The stock saw heavy volatility and mixed analyst signals, with “Strong Sell” ratings alongside momentum-driven “Buy” calls. The Israel-based biotech has no approved products.
4 December 2025
···
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics shares surged 8.5% to $56 on December 3, landing mid-range between their 52-week low of $30 and high of $78. The company reported a $106 million Q3 net loss on $0.9 million in revenue but holds $1.9 billion in cash. Takeover rumors persist, though no formal bids have emerged. Wall Street price targets range widely, with consensus in the high-$60s to mid-$70s.
4 December 2025
·
Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics shares surged over 300% to nearly $30 after Phase 3 data showed its Deramiocel cell therapy slowed upper-limb decline by 54% and preserved 91% of heart function in Duchenne muscular dystrophy patients. The HOPE-3 trial enrolled 106 mostly non-ambulatory boys and young men. Trading was volatile, with the stock flagged as “extremely overbought.”
4 December 2025
··
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb shares jumped over 6% to $51.32 intraday on December 3, 2025, after the company announced a data review and patient re-enrollment for its ADEPT-2 Alzheimer’s psychosis trial. The stock rally follows strong Q3 results and analyst upgrades, despite ongoing legal risks and looming patent expiries.
3 December 2025
····
Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics shares jumped over 380% Wednesday after reporting positive Phase 3 HOPE-3 trial results for deramiocel in Duchenne muscular dystrophy. The stock opened near $30, up from $6.36, hitting intraday highs around $40 on volume over 40 million shares. The FDA previously rejected deramiocel but will review new data for possible approval in 2026. Capricor ended Q3 with $98.6 million in cash.
3 December 2025
···
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics shares surged over 500% on December 3, 2025, after its Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met all primary and key secondary endpoints. The trial showed a 54% slowing of upper limb decline and 91% preservation of heart function versus placebo. Capricor plans to resubmit its BLA to the FDA, addressing a previous Complete Response Letter. The stock traded around $39–40 intraday, up from $6.36.
3 December 2025
···
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd shares surged 130% on December 2 after announcing a manufacturing upscaling milestone for its PL‑14 nasal allergy blocker. The stock closed at $7.33, up from $3.16, with trading volume near 150 million shares. The Israeli biotech, which has no approved products or revenue, now trades around $6 pre-market. Polyrizon develops intranasal hydrogel sprays and remains in the pre-commercial stage.
3 December 2025
··
Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen shares traded at $338.67 on December 2, 2025, up 0.35% and near 52-week highs after strong Q3 results and a raised 2025 outlook. Several institutional investors disclosed reduced AMGN holdings in Q2 filings. Technical analysts flagged a short-term bullish setup. The company’s obesity and cardiovascular drugs remain key pipeline drivers.
2 December 2025
···
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio shares surged up to 13% on November 28 after reporting Q3 revenue of $32.1 million, up from $6.1 million a year earlier, driven by Anktiva sales. The company posted a Q3 net loss of $67.3 million and a nine-month cash outflow of $234.6 million. Anktiva is FDA-approved for certain bladder cancer patients in the U.S. and recently gained UK approval. Shares remain down mid-teens for the year.
29 November 2025
···
HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

HKEX shares closed at HK$414.80 on November 27, 2025, up 0.4% amid derivatives expiries and anticipation of Hang Seng Biotech Index futures. The stock traded between HK$410.00 and HK$416.00 on about 1.8 million shares. HKEX is up roughly 40–45% year-on-year, trading in the upper half of its 52-week range. The Hang Seng Index ended at 25,942.5, up 0.06%.
27 November 2025
··
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical data showing its lead drug Telomir-1 killed HL60 leukemia cells in vitro. Director Dr. Craig Eagle resigned from the board, effective November 14, with no dispute cited. TELO stock jumped 8% pre-market but recently traded at $1.39, down 3% from the prior close. Shares remain down about two-thirds year-to-date.
21 November 2025
··
Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (SHPH) Stock Soars on S‑1 Filing, Fresh Financing and AI Pivot – What Today’s Volatile Rally Means for Investors (21 Nov 2025)

Shuttle Pharmaceuticals (NASDAQ: SHPH) jumped over 25% in after-hours and pre-market trading on November 21, 2025, after filing a new S-1 registration statement. The filing registers 625,156 shares tied to a pre-funded warrant held by Alternative Investment Capital Inc., which could control about 47% of shares post-offering. Shuttle will not receive new proceeds, as cash was raised in a prior $2.5 million private placement.
21 November 2025
···
1 … 8 9 10 11 12 … 16

Stock Market Today

  • Silicon Motion (SIMO) Rises Despite Market Downturn, Strong Earnings Anticipated
    March 19, 2026, 7:45 PM EDT. Silicon Motion (SIMO) closed up 1.67% at $127.50, outperforming the S&P 500's 0.28% decline. Despite a 5.54% drop over the past month, SIMO is set for a significant earnings report, with analysts predicting $1.23 per share - a 105% year-over-year surge. Revenue is expected to reach $299.61 million, up nearly 80% from last year. Full-year projections show earnings of $5.8 per share and revenues hitting $1.27 billion, marking growth of 63% and 43% respectively. The stock holds a Zacks Rank #1 (Strong Buy), with recent upward estimate revisions signaling confidence. SIMO trades at a forward price-to-earnings (P/E) ratio of 21.61, slightly above its industry average, and maintains a PEG ratio of 0.77, matching its sector. The Computer - Integrated Systems industry ranks in the top 10%, underpinning favorable future performance prospects.
Go toTop